

## HIV Glasgow 2024: Scientific Programme

### Sunday 10 November

|                   |  |
|-------------------|--|
| 10:30–12:00       | <b>Workshop</b>  |
| 10:30–12:00       | <b>Workshop</b>  |
| 12:00–12:30       | <b>Coffee</b>  |
| 12:30–13:30       | <b>Industry Symposium</b>  |
| 13:30–14:15       | <b>Lunch, Posters and Exhibition</b>   |
| 14:15–15:15       | <b>Industry Symposium</b>  |
| 15:15–15:30       | <b>Coffee</b>  |
| 15:30–17:00       | <b>Industry Symposium</b>  |
| 17:00–17:30       | <b>Coffee, Posters and Exhibition</b>  |
| 17:30–17:50       | <b>Official Opening, Welcome from Glasgow City, and Outcomes, public health responses, lessons learned and current status of the Glasgow HIV outbreak (10 year overview)</b>   |
| 17:30–17:40       | <i>Alexandra Calmy, HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</i><br><i>Chloe Orkin, Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i> |
| 17:40–17:45       | <b>Bailie Annette Christie, Glasgow City Council, Glasgow, UK</b><br>and   |
| 17:45–17:50       | <b>Erica Peters, Infectious Diseases Department, NHS Greater Glasgow and Clyde, Glasgow, UK</b>  |
| 17:50–19:00       | <b>Stigma in HIV, Past, Present and Future. Stereotyping Patients: Impact on HIV Treatment</b>   |
| <b>Co-chairs:</b> | <b>Alexandra Calmy</b><br><b>Chloe Orkin</b>   |
| 17:50–17:55       | <b>Welcome and Introduction</b><br><b>Chloe Orkin</b>  |
| 17:55–18:10       | <b>HIV-related stigma and discrimination in the healthcare setting in Europe and Central Asia</b><br><b>Teymur Noori, HIV and Migrant Health, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</b>                         |
| 18:10–18:25       | <b>Title TBC</b><br><b>Rigmor C Berg, Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway</b>  |
| 18:25–18:40       | <b>The Stigma Spectrum: Past Lessons For Future Solutions</b><br><b>Angelina Namiba, 4M Mentor Mothers Network, London, UK</b>   |
| 18:40–19:00       | <b>Panel Discussion and close</b>  |
| 19:00–20:00       | <b>Civic Reception hosted by the Lord Provost Jacqueline McLaren and Glasgow City Council</b>  |

## Monday 11 November

- 08:30–09:45 **Experience in the Implementation of Long-Acting Treatment Session in collaboration with the International AIDS Society**  
**Co-chairs:** Cissy Kityo, *Joint Clinical Research Centre, Kampala, Uganda*  
Simon Collins, *HIV i-Base, United Kingdom*
- 08:30–08:35 **Welcome and Introduction**  
Cissy Kityo
- 08:35–18:45 **Long-acting treatment for virally suppressed individuals**  
Chloe Orkin, *Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK*
- 08:45–09:00 **Long-acting treatment for non-virally suppressed individuals on cabotegravir + rilpivirine: real world evidence**  
Monica Gandhi, *Division of HIV, Infectious Diseases, and Global Medicine at University of California San Francisco / San Francisco General Hospital, San Francisco, CA, USA*
- 09:00–09:10\* **O21: Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: week 48 safety, efficacy, and metabolic changes**  
Amy E Colson, *Community Resource Initiative, Boston, MA, USA*
- 09:10–09:20\* **O22: Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirin**  
Arkaitz Imaz, *Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain*
- 09:20–09:30\* **O23: Efficacy and safety analysis of lenacapavir with broadly neutralising antibodies, teropavimab and zinlirvimab, in people with HIV-1 highly sensitive to one or both broadly neutralising antibodies**  
Paul P Cook, *Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA, USA*
- 09:30–09:45 **Panel discussion and close**  
All
- 09:45–10:15 **Coffee, Posters and Exhibition**
- 10:15–11:15 **Managing Cardiometabolic Risk in HIV: The Role of Old and New Drugs**  
**Co-chairs:** Bernard Surial, *Department of Infectious Diseases, University Hospital of Bern, Bern, Switzerland*  
Andrew Carr, *Immunology and HIV Unit, St Vincent's Hospital; and University of New South Wales, Sydney, Australia*
- 10:15–10:20 **Welcome and Introduction**  
Bernard Surial
- 10:20–10:33 **Managing cardiovascular disease risk in HIV**  
Esteban Martínez, *Infectious Diseases Unit, Hospital Clínic de Barcelona, Barcelona, Spain*

- 10:33–10:46 **GLP-1 agonists to mitigate cardiometabolic risk**  
**Christian Delles**, *School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK*
- 10:46–10:59 **Managing ART-associated weight gain in HIV**  
**Cristina Mussini**, *Department of Infectious Diseases and Tropical Medicine, University Hospital, Modena, Italy*
- 10:59–11:15 **Panel discussion and close**  
**All**, joined by **Nadine Jaschinski**, *The International Cohort Consortium of Infectious Disease (RESPOND)*, and **CHIP**, *Rigshospitalet, Copenhagen, Denmark*
- 11:15–12:30 **Elimination of HIV Vertical Transmission Across the World**  
*In collaboration with the Euroguidelines in Central and Eastern Europe (ECEE) Network Group*
- Co-chairs:** **Linda-Gail Bekker**, *Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa*  
**Cristiana Oprea**, *Carol Davila University of Medicine and Pharmacy, Bucharest, and Infectious Diseases and HIV Department, Victor Babes Hospital for infectious and Tropical Diseases, Bucharest, Romania*
- 11:15–11:25 **Welcome and Introduction**  
**Cristiana Oprea**
- 11:25–11:35 **Antiretrovirals in pregnancy and breastfeeding: a research toolkit**  
**Shahin Lockman**, *Brigham and Women's Hospital and Harvard TH Chan School of Public Health, Boston, MA, USA; and Botswana Harvard Health Partnership, Gaborone, Botswana*
- 11:35–11:47 **Human rights and elimination of HIV vertical transmission, including co-infection – insights from Eastern Europe and Central Asia**  
**Justyna Kowalska**, *Department of Adult Infection Diseases, Medical University of Warsaw, Warsaw, Poland; and HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland*
- 11:47–11:59 **Sexual violence, HIV and pregnancy outcomes in South America**  
**Claudia Cortes**, *Faculty of Medicine, University of Chile, Santiago, Chile*
- 11:59–12:11 **Early infant diagnosis and linkage to HIV care for children – are we there yet?**  
**Oxana Turcanu**, *Perinatal Center, Clinical Municipal Hospital "Gheorghe Paladi", Chişinău, Moldova*
- 12:11–12:30 **Panel discussion and close**  
**All**
- 12:30–13:45 **Lunch, Posters and Exhibition**
- 12:45–13:45 **Industry Symposium**
- 13:45–14:30 **Antiretroviral Treatment Strategies**
- Co-chairs:** **Magdalena Ankersztejn-Bartczak**, *Foundation for Social Education, Warsaw, Poland*  
**Alexandra Calmy**, *HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland*
- 13:45–13:50 **Welcome and introduction**  
**Alexandra Calmy**

- 13:50–14:10 **New Treatments and Future Combinations**  
*José Arribas, Infectious Diseases Unit, La Paz Hospital, Madrid, Spain; and School of Medicine, Autonoma University School of Medicine, Madrid, Spain*
- 14:10–14:20\* **O24: Comparable efficacy and safety of dolutegravir/lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm<sup>3</sup>: the DOLCE study**  
*Pedro Cahn, Research Department, Fundacion Huesped, Buenos Aires, Argentina*
- 14:20–14:30 **Panel discussion and close**  
**All**
- 14:30–15:45 **Infection Prevention**
- Co-chairs:** *Iskandar Azwa, University Malaya, Kuala Lumpur, Malaysia*  
*Georg Behrens, Hannover Medical School, Hannover, Germany*
- 14:30–14:35 **Welcome and introduction**  
**Iskandar Azwa**
- 14:35–14:45 **A provider's perspective of DoxyPEP**  
*Jade Ghosn, Department of Infectious Diseases, Bichat University Hospital, Paris, France*
- 14:45–14:55 **A DoxyPEP perspective from the community**  
*Sophie Strachan, The Sophia Forum, London, UK; and Chelsea and Westminster Hospital NHS Foundation Trust, London, UK*
- 14:55–15:05\* **O25: Post-exposure prophylaxis with doxycycline (DoxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI). The PRIDOX study**  
*Rosario Palacios, Hospital Universitario Virgen de la Victoria, Infectious Diseases Unit, IBIMA, Málaga, Spain*
- 15:05–15:20 **Mpox: 2024 update**  
*Dimie Ogoina, Bayelsa Medical University, Yenagoa, Nigeria*
- 15:20–15:30\* **O26: Both smallpox MVA vaccine and mpox infection produce potent immune response to mpox in people living with HIV**  
*Maryam Khan, SHARE Collaborative, Immunobiology, Blizard Institute, Queen Mary University of London, London, UK*
- 15:30–15:45 **Panel discussion and close**  
**All**
- 15:45–17:00 **Supporting an Older Population of People Living With HIV, or at Risk of HIV**  
***In collaboration with the British HIV Association***
- Co-chairs:** *Giovanni Guaraldi, Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy*  
*Nicoletta Policek, UK Community Advisory Board (UK-CAB), UK, and European AIDS Treatment Group, Brussels, Belgium*
- 15:45–15:50 **Welcome and Introduction**  
**Giovanni Guaraldi**
- 15:50–16:00 **Global perspectives on HIV in older people**  
*Caroline Sabin, Institute for Global Health, University College London (UCL), London, UK*

- 16:00–16:10 **Models of care for older people with HIV**  
Tristan Barber, *Ian Charleson Day Centre, Royal Free Hospital, London, UK*
- 16:10–16:20 **Are we adequately supporting women ageing with HIV?**  
Yvonne Gilleece, *Claude Nicol Centre (Sexual Health) and Lawson Unit (HIV), Brighton and Sussex University Hospitals NHS Trust, Brighton, UK*
- 16:20–16:30 **PrEP in older people at risk of HIV acquisition**  
Juddy Otti-Olunga, *HIV Services, Africa Advocacy Foundation, and The Sophia Forum, London, UK*
- 16:30–16:40 **Adults with perinatally acquired HIV: emerging clinical outcomes and data gaps**  
Merle Henderson, *Clinical Trials Centre, Imperial College Healthcare NHS Trust, London, UK*
- 16:40–17:00 **Panel discussion and close**  
All, led by Nicoletta Policek

17:00–17:30 **Coffee, Posters and Exhibition**

17:30–19:00 **Industry Symposium**

## Tuesday 12 November

08:30–09:30 **Industry Symposium**

09:30–09:45 **Coffee, Posters and Exhibition**

09:45–11:10 **Integrase Strand Transfer Inhibitor (INSTI) Resistance**

**Co-chairs:** Anton Pozniak, *Chelsea and Westminster Hospital, London, UK*  
Marco Vitoria, *Department of HIV/AIDS, World Health Organization, Geneva, Switzerland*

09:45–09:50 **Welcome and Introduction**  
Anton Pozniak

09:50–10:05 **INSTI resistance global data trends**  
Daniel Kuritzkes, *Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA*

10:05–10:20 **2<sup>nd</sup> generation INSTI resistance in randomized trials and cohorts**  
Andrew Hill, *Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK*

10:20–10:35 **HIV drug resistance testing: new strategies and the promise of new technologies**  
Gert van Zyl, *Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa*

10:35–10:45\* **O31: Clinical features and resistance patterns during second-generation INSTI failure: the ROSETTA-registry**  
Mafalda NS Miranda, *Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands*

- 10:45–10:55\* **O32: Virological outcomes and associated factors among treatment-naive patients with HIV-1 on dolutegravir based regimen in a programmatic setting in Thailand**  
**Napon Hiranburana**, *HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Hiranburana, Bangkok, Thailand*
- 10:55–11:10 **Panel discussion and close**  
**All, Led by Marco Vitoria**, *Department of HIV/AIDS, World Health Organization, Geneva, Switzerland*
- 11:10–11:40 **HIV in migrant populations**  
*The Lancet HIV*  
 A ‘fireside chat’ between the session moderator and invited guests to learn more about *The Lancet HIV*’s upcoming paper series. The ‘chat’ will discuss how the concept came about, and explore the challenges faced along the way as the series progressed.
- Moderator:** **Peter Hayward**, *The Lancet HIV, Lancet Group, London, UK*
- Guests:** **Claudia Cortes**, *Faculty of Medicine, University of Chile, Santiago, Chile*  
**Alena Kamenshchikova**, *Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands*
- 11:40–13:00 **Clinical Case Study Session**  
**In collaboration with the Liverpool DDI team**
- Facilitators:** **Roy Gulick**, *Department of Medicine, Weill Cornell Medicine, New York, NY, USA*  
**Saye Khoo**, *Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK; and Royal Liverpool University Hospital, Liverpool, UK*  
**Catia Marzolini**, *Department of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; and Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; and School of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK*
- Panellists:** **Marta Boffito**, *Clinical Research Facility / HIV Service, Chelsea and Westminster Hospital, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK*  
**Lene Ryom**, *Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark*  
**Karine Lacombe**, *Department of Infectious Diseases, Hospital Saint Antoine, Paris, France*
- 11:40–11:55 **Celebrating 25 years of the work of the Liverpool DDI Team**  
**Saye Khoo and David Back**, *Emeritus Professor, Department of Pharmacology, University of Liverpool, Liverpool, UK*
- 11:55–12:15 **Case 1: Seroconversion on long-acting PrEP**  
**Jean-Michel Molina**, *University of Paris, Paris, France; and Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, Paris, France*
- 12:15–12:35 **Case 2: Low CV risk – statins case**  
*Do you use them and what about DDIs?*  
**Laura Waters**, *Mortimer Market Centre, University College London Hospitals NHS Foundation Trust, London, UK*
- 12:35–12:55 **Case 3: TB with ART?**  
**Catherine Orrell**, *Antiretroviral Treatment Division (ART), Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa*

|                   |   |
|-------------------|---|
| 12:55–13:00       | <b>Close</b><br><b>Saye Khoo</b>  |
| 13:00–14:15       | <b>Lunch, Posters and Exhibition</b>  |
| 13:15–14:15       | <b>Industry Symposium</b>   |
| 14:15–15:15       | <b>HIV Cure: Where Are We Now?</b>  |
| <b>Co-chairs:</b> | <b>Peter Reiss</b> , <i>Amsterdam UMC, University of Amsterdam in Amsterdam, The Netherlands</i><br><b>Alain Volny-Anne</b> , <i>Paris, France</i>  |
| 14:15–14:20       | <b>Welcome and introduction to this year’s Joep Lange and Jacqueline van Tongeren keynote lecture, dedicated to them in recognition of their commitment and passion to rid the world of HIV/AIDS</b><br><b>Peter Reiss</b>  |
| 14:20–14:45       | <b>Keynote Lecture – HIV cure: Lessons learnt and prospects for the future</b><br><b>Linos Vandekerckhove</b> , <i>Department of Internal Medicine and Pediatrics, HIV Cure Research Center, University Hospital Ghent, Ghent University, Ghent, Belgium</i>  |
| 14:45–15:00       | <b>Ethics in trials of HIV cure</b><br><b>Karine Dubé</b> , <i>School of Medicine and Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA</i>  |
| 15:00–15:15       | <b>Panel discussion</b><br><b>All joined by Sarah Fidler</b> , <i>Imperial College NHS Trust, and Imperial College London, London, UK</i>   |
| 15:15–16:00       | <b>Keynote Lecture: Artificial Intelligence and Digital Technologies: Their Role in Future HIV Research, Treatment and Care</b>   |
| <b>Chair:</b>     | <b>Peter Hunt</b> , <i>University of California, San Francisco, United States</i><br><br><b>Alastair C Van Heerden</b> , <i>Center for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa; and SAMRC/Wits Developmental Pathways for Health Research Unit, University of the Witwatersrand, Johannesburg, South Africa</i> |
| 16:00–17:00       | <b>Emerging Ethical and Participation Challenges in HIV Research and Development in collaboration with the European AIDS Treatment Group (EATG)</b>   |
| <b>Co-chairs:</b> | <b>Nicoletta Policek</b> , <i>European AIDS Treatment Group, Brussels, Belgium</i><br><b>Mario Cascio</b> , <i>EATG, Palermo, Italy</i>   |
| 16:00–16:05       | <b>Welcome and introduction</b><br><b>Nicoletta Policek</b>   |
| 16:05–16:15       | <b>The challenges of ATI in HIV cure research from the community perspective</b><br><b>Gus Cairns</b> , <i>London, UK</i>   |
| 16:15–16:25       | <b>Engagement with the community</b><br><b>Grzegorz Jezierski</b> , <i>Lambda Warszawa, Warsaw, Poland</i>  |
| 16:25–16:35       | <b>Bridging the gap: Ensuring gender equity in clinical trials for better health outcomes</b><br><b>Oana Săndulescu</b> , <i>Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</i>  |

16:35–16:45 **Broadening horizons: Enhancing transgender inclusion and global diversity in clinical trials**  
*Amanita Calderón Cifuéntes, Transgender Europe, Berlin, Germany*

16:45–17:00 **Discussion, Q&A and conclusions**  
All

17:00–17:30 **Coffee, Posters and Exhibition**

17:30–19:00 **Industry Symposium**

## Wednesday 13 November

08:30–09:45 **Guidelines Session: 2024 Update and CV Risk Recommendations**  
*in collaboration with the European AIDS Clinical Society (EACS)*

**Co-chairs:** **Jürgen Rockstroh**, *Department of Medicine I, University Hospital Bonn, Bonn, Germany; and German Centre for Infection Research (DZIF), Bonn, Germany*  
**Juan Ambrosioni**, *HIV/AIDS Unit and Infectious Disease Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain*

08:30–08:35 **Welcome and introduction, and the 2024 EACS guidelines: new format, new content and new terms of reference**  
**Juan Ambrosioni**

08:35–08:45 **Update on ART for treatment and prevention**  
**Laura Levi**, *Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, France*

08:45–08:55 **Update on co-infections, sexually transmitted infections and opportunistic infections**  
**Andrea Mastrangelo**, *Department of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland*

08:55–09:05 **Update on paediatric HIV management, vertical transmission and infant feeding**  
**Steven Welch**, *Department of Paediatrics, Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK*

09:05–09:25 **Co-morbidities: update on cardiovascular and metabolic risk, including statins recommendations and other co-morbidities**  
**Jasmini Alagaratnam**, *Department of Sexual Health & HIV, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK*

09:25–09:45 **Panel discussion and closing remarks**  
**Esteban Martínez**  
**Catia Marzolini**  
**Luís Mendão**, *GAT – Portuguese Activist Group on Treatments, Lisbon, Portugal*  
**Cristiana Oprea**  
**Steven Welch**

09:45–10:15 **Coffee, Posters and Exhibition**

|                   |   |
|-------------------|---|
| 10:15–11:45       | <b>Co-morbidities and Co-infections</b>   |
| <b>Chair:</b>     | <b>Milosz Parczewski</b> , <i>Pomeranian Medical University, Szczecin, Poland</i>   |
| 10:15–10:30*      | <b>O41: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the National Prospective Real-World ONCOVIHAC ANRS CO24 cohort study</b><br><b>Jean-Philippe Spano</b> , <i>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, and Département d'Oncologie Médicale, Hôpital Pitié-Salpêtrière, Paris, France</i>  |
| 10:30–10:45*      | <b>O42: Depression and anxiety symptoms among people with HIV in the UK: prevalence, correlates and treatment. Results from the Positive Voices 2022 study</b><br><b>Fiona Lampe</b> , <i>Institute for Global Health, University College London, London, UK</i>  |
| 10:45–11:00*      | <b>O43: Randomised, multicentre, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virological control and neuropsychiatric comorbidities: week 24 results from the GESIDA 11920 - MIND study</b><br><b>Ignacio Pérez Valero</b> , <i>Hospital Universitario Reina Sofia, IMIBIC, CIBERINFEC, Enfermedades Infecciosas, Cordoba, Spain</i> |
| 11:00–11:15*      | <b>O44: A phase 3 randomised study to evaluate the safety, tolerability and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine (PCV), followed by PCV15, in adults living with HIV (STRIDE-7)</b><br><b>Moti Ramgopal</b> , <i>Infectious Diseases, Midway Immunology and Research Center, Fort Pierce, FL, USA</i>   |
| 11:15–11:30*      | <b>O45: Prevalence trends of active HCV infection among people with HIV in Spain (2002-2023): nearing elimination</b><br><b>Juan Berenguer</b> , <i>Infectious Diseases, Hospital Gregorio Marañón, IISGM, CIBERINFEC, Madrid, Spain</i>  |
| 11:30–11:45*      | <b>O46A: Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study</b><br>and<br><b>O46B: HIV-positive donor to positive recipient kidney transplantation: a nationwide survey</b><br><b>Jose M Miro</b> , <i>Infectious Diseases Service - HIV/AIDS Unit, Hospital Clinic-Institut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain</i>                     |
| 11:45–12:50       | <b>PrEP-ing for the Future</b>  |
| <b>Co-chairs:</b> | <b>Alexandra Calmy</b> , <i>HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</i><br><b>Chloe Orkin</b> , <i>Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i>  |
| 11:45–12:05       | <b>Keynote Lecture: PrEP Therapeutic Agents - What's on the Horizon and Access?</b><br><i>Lock Lecture gifted by the Royal College of Physicians and Surgeons of Glasgow</i><br><b>Linda-Gail Bekker</b> , <i>Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</i>   |

- 12:05–12:15\* **O47: Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis**  
**Haoyi Wang**, *Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands*
- 12:15–12:25\* **O48: Persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 Phase 3 trial**  
**Linda-Gail Bekker**
- 12:25–12:35\* **O49: Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)**  
**Onyema Ogbuagu**, *Department of Infectious Diseases and Pharmacology, Yale School of Medicine, New Haven, CT, USA*
- 12:35–12:50 **Panel discussion**  
**All**
- 12:50–13:00 **Congress close**
- 13:00–13:45 **Lunch, Posters and Departures**